Onco Wiki / Maladie

Carcinome cervical (prédominant squame + adeno)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-CERVICAL
TypeMaladie
Alias
Carcinome cervicalCarcinome du col de l'utérusКарцинома шийки матки
Étatreviewed 2026-04-26 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-ESMO-CERVICAL-2024 SRC-NCCN-CERVICAL-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8070/3
icd_o_3_topography["C53"]
icd_10C53
who_classificationWHO Female Genital Tumours 5th ed (2020): Cervical squamous cell carcinoma + cervical adenocarcinoma

Capacités

Notes

Scaffolded for batch #2: focus on locally-advanced (FIGO IB3-IVA) CRT and metastatic 1L systemic. Cervical is the second etiologically_driven disease in KB (after HCV-MZL); HPV is the near-universal causal agent. 4 RFs: hydronephrosis-from-pelvic-mass (organ-dysfunction emergency), HIV-coinfection (infection-screening + prognostic), bulky-disease (high-risk biology), frailty/age. Regimens: cisplatin-radiosensitization (concurrent CRT), pembro+chemo+bev (KEYNOTE-826 metastatic), tisotumab vedotin (innovaTV-301 2L+). Out-of-scope this commit: early-stage IA1-IB2 conservative surgery (cone, simple/modified-radical hysterectomy) — Surgery entity per PROPOSAL §17 needed; brachytherapy as separate modality.

Utilisé par

Pertinence thérapeutique

Algorithmes

Maladie

Indication

Questionnaires

Signal d’alerte

Sources